1. Department of General Surgery, Shenzhen University General Hospital / Shenzhen University Clinical Medical Academy, Shenzhen, Guangdong 518055, China. 2. Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. 3. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore 117593. 4. Advanced Medical Initiatives, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. 5. Hepato-pancreato-biliary Surgery Department, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518055, China. 6. Department of Critical Care Medicine, National Cancer Center/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, China. 7. Cancer Center of Kyushu University Hospital, Fukuoka 812-8582, Japan. 8. NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore 117593. 9. National University Cancer Institute, National University Health System, Singapore 119074. 10. Carson International Cancer Research Centre, Shenzhen University School of Medicine, Shenzhen, Guangdong 518055, China. *These authors contributed equally to this article.
✉ Corresponding authors: Kenoki Ohuchida, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan. E-mail: kenokimed.kyushu-u.ac.jp; Peng Gong, Department of General Surgery, Shenzhen University General Hospital/Shenzhen University Clinical Medical Academy, 1098 Xueyuan Road, Shenzhen, Guangdong 518055, China. E-mail: doctorgongpengedu.cn; Masafumi Nakamura, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan. E-mail: mnakamed.kyushu-u.ac.jp.More
Citation:
Zheng B, Qu J, Ohuchida K, Feng H, Chong SJF, Yan Z, Piao Y, Liu P, Sheng N, Eguchi D, Ohtsuka T, Mizumoto K, Liu Z, Pervaiz S, Gong P, Nakamura M. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer: Erratum. Theranostics 2021; 11(20):10171-10172. doi:10.7150/thno.68023. https://www.thno.org/v11p10171.htm
Zheng, B., Qu, J., Ohuchida, K., Feng, H., Chong, S.J.F., Yan, Z., Piao, Y., Liu, P., Sheng, N., Eguchi, D., Ohtsuka, T., Mizumoto, K., Liu, Z., Pervaiz, S., Gong, P., Nakamura, M. (2021). LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer: Erratum. Theranostics, 11(20), 10171-10172. https://doi.org/10.7150/thno.68023.
ACS
Zheng, B.; Qu, J.; Ohuchida, K.; Feng, H.; Chong, S.J.F.; Yan, Z.; Piao, Y.; Liu, P.; Sheng, N.; Eguchi, D.; Ohtsuka, T.; Mizumoto, K.; Liu, Z.; Pervaiz, S.; Gong, P.; Nakamura, M. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer: Erratum. Theranostics 2021, 11 (20), 10171-10172. DOI: 10.7150/thno.68023.
NLM
Zheng B, Qu J, Ohuchida K, Feng H, Chong SJF, Yan Z, Piao Y, Liu P, Sheng N, Eguchi D, Ohtsuka T, Mizumoto K, Liu Z, Pervaiz S, Gong P, Nakamura M. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer: Erratum. Theranostics 2021; 11(20):10171-10172. doi:10.7150/thno.68023. https://www.thno.org/v11p10171.htm
CSE
Zheng B, Qu J, Ohuchida K, Feng H, Chong SJF, Yan Z, Piao Y, Liu P, Sheng N, Eguchi D, Ohtsuka T, Mizumoto K, Liu Z, Pervaiz S, Gong P, Nakamura M. 2021. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer: Erratum. Theranostics. 11(20):10171-10172.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.